Abstract. Dihydrotestosterone-receptor com-plexes formed in human fibroblast cytosol prepared at 00C in the presence of sodium molybdate can be readily transformed to the DNA-binding state by heating at 250C. Under these conditions 50-70% of dihydrotestosteronereceptor complexes bind to DNA. We describe here studies of the transformation process in cytosols derived from normal cells and from fibroblasts propagated from subjects with syndromes ofandrogen resistance. In contrast to the situation with dihydrotestosterone, normal testosteronereceptor complexes are unstable under in vitro transforming conditions. Although equal amounts ofhormonereceptor complex are formed at 00C, only 15% of testosterone-receptor complexes remain stable and acquire DNA-binding capacity after warming. This instability is not reversible upon lowering the temperature and is corrected by low concentrations (0.25 gM) of the protease inhibitor leupeptin. We have also identified two cousins with androgen resistance whose androgen-receptor complexes exhibit similar in vitro transformation lability with both dihydrotestosterone and testosterone. Phenotypic evidence in these subjects indicates that dihydrotestosterone-mediated processes are more completely impaired than are testosterone-mediated events. These findings This work has been published in abstract form (Clin. Res. 31:471, 1983 suggest that dihydrotestosterone may amplify the androgenic signal at its targets not only by its higher affinity for the receptor but also by its more efficient conversion to the DNA-binding state and that such amplification may be less critical in target tissues in which testosterone suffices for androgenic effect. This offers one possible explanation of how a mutation that affects a single receptor protein may differentially impair the actions of two binding ligands of the receptor.
Introduction
The syndromes ofandrogen resistance are characterized by normal or greater than normal production of testicular androgens but ineffective action of these hormones in target tissues. The clinical spectrum of these disorders ranges from complete failure of male phenotypic development (complete testicular feminization) to isolated defects of spermatogenesis in otherwise normal men (1) . In vitro correlates ofthese phenotypes have been studied in cultured skin fibroblasts, and some ofthe defects in androgen action have been characterized. Known abnormalities include quantitative deficiencies of androgen binding, qualitative abnormalities thought to result from structural alterations in the receptor, and a few instances in which the androgen receptor appears to be normal in amount and function, implying an abnormality in some subsequent step in androgen action (1) .
To provide additional insight into the events in androgen action that follow binding ofthe steroid to the receptor we have recently examined in vitro the process termed "transformation" by which androgen-receptor complexes of human fibroblast cytosol acquire the capacity to bind to DNA (2) . The transformation of steroid-receptor complexes to the DNA-binding state is thought to be a necessary step in steroid hormone action.
The chemical nature of this reaction is unknown, but it appears to involve a conformational change in the receptor protein that results in an alteration in net charge and permits the receptor-hormone complex to bind to polyanionic substances such as DNA (3) .
We report here comparative studies of the ability of testosterone-receptor and dihydrotestosterone-receptor complexes from normal cytosol to undergo transformation to the DNAbinding state. In addition, we have studied the transformation phenomenon in fibroblasts from subjects with androgen resistance in whom the amount of cytosolic receptor is sufficient to allow measurement of binding of the hormone-receptor complexes to DNA. We have identified a subset of subjects with qualitatively abnormal androgen receptors in whom the androgen-receptor complex is unstable under transforming conditions. The defect in these subjects appears to impair dihydrotestosterone-mediated events more severely than testosteronemediated processes.
Methods
Materials. [1, 2, 4, 5, 6 ,73H]Dihydrotestosterone (17fl-hydroxy-5a-androstan-3-one) and [1, 2, 4, 6 7 .15); TEGM-l0 (TEGM containing 10 mM NaCI and 0.2 mg/ml bovine serum albumin); TEGM containing 300 mM NaCI and 0.2 mg/ml bovine serum albumin. The pH of all buffers was adjusted at room temperature (23°C), and the buffers were stored and used at 0°C.
Cell culture. Fibroblasts were grown as described (4) from explants ofgenital skin obtained at circumcision or from biopsies. After monolayer cultures became confluent (day 6 after plating) the standard medium was changed to medium without added serum, and the experiments were performed 1 d later.
The cell strains used in these experiments were all derived from labia majora, foreskin, or scrotum and are listed in Table I . The 18, and 79) and three (strains 16, 500, and 512) in which the androgen receptor is qualitatively abnormal (5) .
Strain 500 was from a 4-yr-old, 46,XY patient of Dr. David Brown of the University of Minnesota, Minneapolis; the boy had microphallus, perineoscrotal hypospadias, and cryptorchidism, normal response of plasma androgens to human chorionic gonadotropin, and normal Sareductase activity in cultured skin fibroblasts. The high affinity androgen receptor is normal in amount but is qualitatively abnormal as evidenced by a failure of molybdate to stabilize the 8S receptor complex on sucrose density gradients (5) ( Table I) .
Cell strain 16 was derived from a labia majora biopsy of 46,XY infant (subject MW) who was evaluated by two of us (Drs. Carlson and Weaver) at I mo of age. On physical examination the child was found to have a small phallus (1 cm) and a bifid scrotum with palpable testes.
The urethral opening was on the perineum. After an human chorionic gonadotropin stimulation test (2,000 U daily for 3 d) plasma testosterone rose to 462 ng/dl. A female sex assignment was agreed upon by parents and physicians. At surgery, normal epididymides and vasa deferentia were identified, and no mullerian structures were found. Bilateral gonadectomy and inguinal herniorrhaphy were performed. The microscopic examination of the resected tissues showed normal testes, epididymides, and vasa deferentia. On the basis of the clinical findings, a diagnosis of male pseudohermaphroditism due to androgen resistance was made. A maternal cousin with an apparently identical phenotype had been born 3 yr earlier, labia majora biopsy was subsequently obtained on this subject as well (strain 512).
Monolayer binding assays. On the day of the experiment the monolayers of fibroblasts (6-cm diam. wells) were rinsed with 2 ml of media without serum and incubated at 37°C for 60 min with media containing various concentrations (0.2-3.0 nM) of [3H]dihydrotestosterone. The cells were rinsed, harvested with trypsin-EDTA, and sonicated. Aliquots were taken for measurement of radioactivity and protein. Total dihydrotestosterone binding was plotted as a function of steroid concentration, and B.., or amount of high-affinity binding was calculated as before (4) by extrapolating the plateau portion of the binding curve to the ordinate. Experiments in which thermolability was assessed in monolayers were similar except that incubations were carried out at both 370 and 42°C. All media and dishes were separately incubated at these temperatures. A >40% decrease in B at 420 relative to 37°C was considered evidence for thermolability (5, 6) . Intranuclear localization of [3Hldi-hydrotestosterone in monolayers of intact cells was assessed by a procedure previously described (7) except that a single saturating concentration of ligand was used for estimation of total and nonspecific binding. DNA was measured by the method of Kissane and Robbins (8) .
Preparation ofcytosol. Confluent monolayers ofcells (in 15-cm dishes) were washed twice with 4 ml of ice-cold 20 mM Tris-150 mM NaCI (Tris-saline) and harvested by scraping with a rubber policeman in 4 ml ofthe same solution. The pooled cells were pelleted by centrifugation at 480 g for 4 min at 4°C. The pellet was washed with two more times with Tris-saline and once with 20 mM Tris HCI, 1 mM EDTA, and 1 mM mercaptoethanol, pH 7.15. The cell pellet was suspended in an equal volume of TEGM containing 5 mM Na2MoO4 and homogenized in a glass Dounce homogenizer on ice with 15 strokes ofthe tight pestle. The homogenate was diluted as needed for various experiments with TEGM + 5 mM Na2MoO4 and centrifuged at 100,000 g for 60 min. The supernatant from this centrifugation was used for all studies of the cytosolic androgen receptor. Protein concentration in the cytosol averaged 2-4 mg/ml.
Androgen binding assays in cytosol. Lowry et al. (9) , using bovine serum albumin as standards.
(b) Hydroxylapatite assay. Aliquots (0.5 ml) of a 50% suspension of washed hydroxylapatite in TEGM containing 5 mM Na2MoO4 were added to 0.2-ml aliquots of cytosol containing radioactive steroid. The mixture was kept at 0C for 30 min and stirred every 10 min. The tubes were centrifuged at 480 g for 5 min and the supernatant was discarded. The hydroxylapatite pellets were washed three times with 2 ml ofTEGM containing 5 mM Na2MoO4 and 0.5% Triton X-100. After the final wash the hydroxylapatite pellet was extracted with I ml of 100% ethanol for 30 min at room temperature. After centrifugation, aliquots of the supernatant were assayed for radioactivity.
(c) Gelfiltration. Aliquots of cytosol containing radioactive steroid (0.2 ml) were applied to 5-ml columns (bed volume) of Sephadex G-25 equilibrated with TEGM. The columns were eluted with TEGM, and five drop fractions were collected in minivials. Scintillation mixture (3.5 ml) was added to each vial, and the samples were assayed for radioactivity. The sum of radioactivity eluting in the void volume of the column was computed. Nonspecific binding was estimated in samples incubated with a 500-fold excess of nonradioactive hormone.
Sucrose density gradient centrifugation. Aliquots (0.2 ml) of cytosol that had been incubated for 3 h at 0°C with [3H]dihydrotestosterone were treated with charcoal as above and applied to continuous gradients (4.9 ml) of 5-20% sucrose in TEGM. Some gradients also contained 10 mM Na2MoO4 or 0.3 M KCI. ['4C]Acetylated albumin (-1,000 dpm) prepared by the method of Montelaro and Rueckert (10) was used as an internal marker on the gradients. The tubes were centrifuged at 250,000 g for 18 h at 0°C in a Beckman ultracentrifuge (Beckman Instruments, Inc., Palo Alto, CA) using the SW50. 1 rotor. The gradients were fractionated from the top into four drop aliquots using an ISCO gradient fractionator (Instrumentation Specialties Co., Inc., Lincoln, NE), and each fraction was assayed for radioactivity in 10 ml of scintillation mixture. In some experiments the gradients contained 3 nM [3H]dihydrotestosterone, and the cytosol was not charcoal treated before centrifugation. In these experiments, bound steroid in each fraction of the gradient was estimated by the hydroxylapatite assay described above.
DNA-cellulose binding assay. DNA-cellulose (1-2 mg of DNA per packed milliliter of cellulose) was prepared by the method of Alberts and Herrick ( 11) and stored at -20°C in TE buffer containing 150 mM NaCI. Denatured DNA was used, as previous experiments showed slightly more binding of receptor to denatured DNA than to the native form (2) . Aliquots were thawed as needed for use. The binding assay was carried out in a cold room at 0°C. DNA-cellulose was diluted to a thin slurry with TEGM-10, packed in l-ml glass syringes to a bed volume of 0.4 ml, and washed with TEGM-I0. Aliquots of cytosol (0.2 ml) that had been incubated with 3H-steroid and subjected to various transforming procedures were applied to the columns. The DNA-cellulose was washed with -30 bed volumes of TEGM-10 until a constant background of radioactivity (<90 dpm/0.5 ml) was attained in the eluate. The [3H]hormone-receptor complexes were eluted with five successive aliquots (0.5 ml) of TEGM containing 300 mM NaCI and 0.2 mg/ml bovine serum albumin. Scintillation mixture (10 ml) was added to each vial, and the samples were assayed for radioactivity. The radioactivity eluting from the column in the high salt wash was summed as a measure of transformed receptor bound to the DNA. In parallel experiments in which aliquots of cytosol were incubated with 3H-steroid plus a 500-fold excess of nonradioactive steroid, no adherence of radioactivity to the DNA was observed.
Thin-layer chromatography. Thin-layer chromatography was performed as before (6) (Fig. 1, A and B) . Dihydrotestosterone-receptor complexes remained stable upon heating at 25°C for 1 h, and a significant proportion (58% in this experiment) was transformed to the DNA-binding state (Fig. 2) . In contrast, [3H]testosterone-receptor complexes formed at 0°C become unstable when heated at 25°C in the presence of saturating concentrations ofligand, and less DNA-binding capacity is generated (14% of original receptor content) (Fig. 2) . Thin-layer chromatography of extracts from these incubations showed that <10% of the radioactive testosterone and dihydrotestosterone were metabolized during the experiment (results not shown).
[3H]Dihydrotestosterone was used in the subsequent studies because it appears to be a more favorable ligand for the generation of transformed androgen-receptor complexes.
Transformation ofdihydrotestosterone-receptor complexes in controls and patients with androgen resistance in these eight control strains appeared to be qualitatively normal by the criteria previously used in this laboratory, namely no thermolability of androgen binding in monolayers and stability upon ultracentrifugation when molybdate was included in the homogenization buffer (5). Several subjects with androgen resistance associated with normal binding in intact monolayer assays but qualitative receptor defects detected by sucrose density gradient centrifugation (5) were found to have receptors that were unstable when broken cell preparations were made in molybdate-containing buffers even at 0°C, and thus were unsuitable for further studies of transformation. However, six individuals with endocrine evidence of androgen resistance had suitable receptors for the assessment of DNA binding (Table I ). This group included three subjects (500, 16, and 512) with qualitative abnormalities of the androgen receptor (failure of molybdate stabilization) and three subjects with no identified abnormality of the androgen receptor (321, 18, and 79) (7). Transformation of androgenreceptor complexes was normal in four of the six subjects, i.e., 58-83% ofthe receptor bound to DNA-cellulose after incubation at 25°C (Table I) . Cytosol from two cell strains from one family (16 and (Fig. 3) (Fig. 4) On sucrose density gradient centrifugation no dihydrotestosterone binding peak was identified in the mutant under a variety of conditions. The same result was obtained whether the sucrose gradient was in TEGM buffer alone or contained 10 mM Na2MoO4 or 0.3 M KC1, additions that cause size shifts of the normal fibroblast androgen receptor (Fig. 6, A (Fig. 6 D) . Mixing experiments were performed to determine whether the lability under transforming conditions was intrinsic to the receptor, due to destructive factors present in the mutant cytosol, or the consequence of a deficiency of some protective factor normally present (Table IV) . No alteration in the DNA-binding capacity of hormone-receptor complexes from either mutant or normal cytosol resulted from admixture. The defect, therefore, appears to be intrinsic to the receptor molecule itself.
The instability of the mutant receptor's interaction with dihydrotestosterone appears to be due to susceptibility to proteolytic degradation under transforming conditions. A number of protease inhibitors were tested for their ability to prevent degradation of the mutant hormone-receptor complex at 25°C. No effect was seen with aprotinin (1 trypsin inhibitor unit/ml), phenylmethylsulfonyl fluoride (1 mM), pepstatin (10 MM), or bacitracin (0.1 mM) (data not shown).
Leupeptin, however, stabilized the hormone-receptor complexes completely at 25°C (Table V) and was effective at concentrations as low as 0.25 ,M. In two control cell strains (486 and 62), leupeptin had only minor effects on the dihydrotestosterone-receptor complex concentration either at 00 or after 25°C incubation, whereas it inhibited the degradation of the mutant receptor (strain 16) at 250C. In addition, leupeptin prevented heat lability of testosterone-receptor complexes from normal cells. At the lowest effective concentration of leupeptin, the amount of receptor binding to DNA after the 25°C-incubation was increased for the mutant receptor but decreased in the control cell strains. We found no concentration of leupeptin that stabilized the mutant receptors but allowed completely normal DNA binding in the normal strains. Therefore, although degradation of the mutant receptor at 250C can be prevented by leupeptin, the failure to restore transformation ofthe mutant androgen-receptor complex to normal may be due to some undefined action of leupeptin rather than an intrinsic inability of the mutant to undergo transformation. On sucrose density gradient centrifugation, a small peak of dihydrotestosterone binding was seen in the 7.5S region when 250 ,uM leupeptin was included in both cytosol and gradient (results not shown).
Discussion
The subjects described here appear to have an uncommon defect of the androgen receptor. Dihydrotesterone binding and intracellular localization of dihydrotestosterone are normal in intact The nature of the process by which steroid hormone-receptor complexes acquire the capacity to bind to nuclear components is unknown. Nuclear localization studies after whole cells are exposed to radiolabeled hormone have been used to identify mutations of the glucocorticoid receptor in cultured lymphoid cell lines (12) , and impaired nuclear retention of androgen has been described by Eil (13) in fibroblasts from patients with androgen resistance. However, normal localization of the hormone in nuclei from intact cells, as occurred in this patient, does not necessarily imply that the steroid-receptor complex is bound to DNA or other nuclear components and could be a passive reflection of the amount of steroid-receptor complex in the cytosol (7) . The use of broken cell techniques, wherein androgen-receptor complexes are prepared in a uniform nontransformed state and then reacted under standard conditions to yield transformed complexes, did provide evidence of a defect in this subject's receptor. Kaufman et al. (14) have also reported normal nuclear localization in an individual believed on indirect grounds to also have defective transformation to the DNAbinding state.
The defect delineated in our subject appears similar to that described in glucocorticoid-resistant lymphoid cell lines by (16) have reported that leupeptin prevents degradation of a 10.5S species of the estrogen receptor from human breast cancers. Similarly, use ofleupeptin permitted the detection ofa small amount ofthe mutant androgen receptor on sucrose density gradient centrifugation in the present study. Interestingly, we observed that the lability of testosterone-receptor complexes from normal cytosol was also corrected with leupeptin. Thus, the interaction oftestosterone with the normal receptor does not confer the same degree of protease resistance as does dihydrotestosterone binding. As noted earlier, we cannot exclude the possibility that leupeptin's effect may involve mechanisms other than inhibition of proteolysis.
These studies provide some perspective on the nature ofthe molecular defects in subjects with measurable amounts of androgen receptor despite clear evidence of androgen resistance. These disorders have been categorized into two groups: those in whom no abnormality has been identified and a group of patients in whom indirect evidence has been ascertained for a mutation that affects the structure of the androgen receptor (5, 6) . However, the previous studies have been limited to methods of assessing the binding of ligand to receptors. The present technique was utilized in the belief that it might provide insight into the subsequent phases ofandrogen-receptor complex action. However, in examining "receptor-positive" mutations of both types we found only two cousins in whom the defect impairs the generation of DNA-binding capacity. In these subjects a receptor with a known marker of qualitative abnormality was shown to form hormone-receptor complexes that are unstable under transforming conditions. No pure defect in DNA-binding capacity was found. Such mutations that affect a DNA-binding site of the receptor but not the steroid-binding site may be rare. However, since our assay system uses heterologous DNA and provides best results using denatured DNA (2) , it seems clear that we are studying a nonspecific and possibly low-affinity interaction. This experimental method obviously lacks the sensitivity to detect alterations that selectively impair high-affinity binding of hormone-receptor complexes to specific segments of the genome. Investigation of such disorders, as have been achieved in the glucocorticoid and progesterone receptor systems (17, 18, 19) , will require the availability ofcloned DNA sequences involved in the regulation of the transcription of specific messenger RNAs induced by the action of androgens.
The data presented here also bear on two related and unresolved problems in androgen physiology. The first has to do with the pathogenesis of syndromes of incomplete androgen resistance. Both embryologic data and study ofthe 5a-reductase deficiency have provided evidence that the action oftestosterone alone is needed for differentiation of the embryonic wolffian duct into vas deferens, seminal vesicle, and epididymis, whereas dihydrotestosterone is required for virilization of the external genitalia (1) . The clinical phenotypes ofthe X-linked syndromes of incomplete androgen resistance cover a spectrum, but in general suggest that dihydrotestosterone-mediated events are more severely impaired than testosterone-mediated processes (e.g., wolffian duct virilization appears to be more normal than the virilization of the external genitalia). This type of androgen resistance is associated with defects in the androgen receptor (5), but, since both testosterone and dihydrotestosterone bind to the same receptor (1, 20, 21) it has been difficult to formulate plausible mechanisms whereby the action of one ligand is selectively impaired. The second (and more general) question is why dihydrotestosterone is necessary for androgen action in some target tissues while testosterone mediates male differentiation in others.
The unexpected finding of transformation-lability of testosterone-receptor complexes of control cells and from cells of a patient whose phenotype indicates adequate testosterone effect during embryogenesis suggests that this action of the hormone in target tissues may be less critically dependent on generation of a stable transformed hormone-receptor complex. The proximity of the testis to the wolffian duct may result in greater local intracellular androgen concentrations, or some other local factors in these target tissues may serve to reinforce an otherwise weak androgenic signal.
Dihydrotestosterone, in addition to its higher binding affinity for the nontransformed receptor, was found to form a more stable DNA-binding complex with the normal receptor. These amplifying effects may be necessary for efficient transmission of the androgenic signal at sites distant from the sources of hormone. The mutation described here, in which phenotypic evidence of defective action of dihydrotestosterone at target tissues is associated with in vitro evidence for transformationlabile dihydrotestosterone-receptor complexes, supports this construction.
This formulation suggests one explanation ofhow a mutation involving a single receptor protein could impair to a different degree the actions of two different ligands of the same receptor.
Further studies of patients with androgen resistance will be necessary to determine whether transformation lability in vitro does indeed have functional significance or is only a new qualitative marker of altered androgen receptor structure.
